Ziv-aflibercept in metastatic colorectal cancer

References

• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• BartlettDLChuECan metastatic colorectal cancer be cured?Oncology (Williston Park)201226326627522545311
   PubMed Web of Science ®Google Scholar
• GallagherDJKemenyNMetastatic colorectal cancer: from improved survival to potential cureOncology2010783–423724820523084
   PubMed Web of Science ®Google Scholar
• CarmelietPJainRKAngiogenesis in cancer and other diseasesNature2000407680124925711001068
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• VerheulHMVoestEESchlingemannROAre tumours angiogenesis-dependent?J Pathol2004202151314694516
   PubMed Web of Science ®Google Scholar
• ZetterBRAngiogenesis and tumor metastasisAnnu Rev Med1998494074249509272
   PubMed Web of Science ®Google Scholar
• FolkmanJAnti-angiogenesis: new concept for therapy of solid tumorsAnn Surg197217534094165077799
   PubMed Web of Science ®Google Scholar
• BergersGBenjaminLETumorigenesis and the angiogenic switchNat Rev Cancer20033640141012778130
   PubMed Web of Science ®Google Scholar
• RafiiSLydenDBenezraRHattoriKHeissigBVascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?Nat Rev Cancer200221182683512415253
   PubMed Web of Science ®Google Scholar
• ZadehGKoushanKBaopingQShannonPGuhaARole of angiopoietin-2 in regulating growth and vascularity of astrocytomasJ Oncol2010201065923120467564
   PubMedGoogle Scholar
• WeidnerNIntratumor microvessel density as a prognostic factor in cancerAm J Pathol199514719197541613
   PubMed Web of Science ®Google Scholar
• CatalanoVTurdoADi FrancoSDieliFTodaroMStassiGTumor and its microenvironment: A synergistic interplaySemin Cancer Biol2013
   Web of Science ®Google Scholar
• FerraraNVascular endothelial growth factor: basic science and clinical progressEndocr Rev200425458161115294883
   PubMed Web of Science ®Google Scholar
• NagyJAVasileEFengDVascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesisJ Exp Med2002196111497150612461084
   PubMed Web of Science ®Google Scholar
• KerbelRSTumor angiogenesisN Engl J Med2008358192039204918463380
   PubMed Web of Science ®Google Scholar
• FerraraNVascular endothelial growth factor as a target for anticancer therapyOncologist20049Suppl 121015178810
   PubMed Web of Science ®Google Scholar
• HicklinDJEllisLMRole of the vascular endothelial growth factor pathway in tumor growth and angiogenesisJ Clin Oncol20052351011102715585754
   PubMed Web of Science ®Google Scholar
• ShweikiDItinASofferDKeshetEVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesisNature199235963988438451279431
   PubMed Web of Science ®Google Scholar
• SunWAngiogenesis in metastatic colorectal cancer and the benefits of targeted therapyJ Hematol Oncol201256323057939
   PubMed Web of Science ®Google Scholar
• KutCMac GabhannFPopelASWhere is VEGF in the body? A meta-analysis of VEGF distribution in cancerBr J Cancer200797797898517912242
   PubMed Web of Science ®Google Scholar
• DvorakHFVascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapyJ Clin Oncol200220214368438012409337
   PubMed Web of Science ®Google Scholar
• ShibuyaMDifferential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesisJ Biochem Mol Biol200639546947817002866
   PubMedGoogle Scholar
• ShibuyaMVascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesisAngiogenesis200694225230 discussion 23117109193
   PubMedGoogle Scholar
• AnisimovALeppänenVMTvorogovDThe basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligandsSci Signal20136282ra5223821770
   PubMed Web of Science ®Google Scholar
• FischerCMazzoneMJonckxBCarmelietPFLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nat Rev Cancer200881294295619029957
   PubMed Web of Science ®Google Scholar
• PavcoPABouhanaKSGallegosAMAntitumor and anti-metastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptorsClin Cancer Res2000652094210310815937
   PubMed Web of Science ®Google Scholar
• HiratsukaSMaruYOkadaASeikiMNodaTShibuyaMInvolvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesisCancer Res20016131207121311221852
   PubMed Web of Science ®Google Scholar
• CarmelietPMoonsLLuttunASynergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditionsNat Med20017557558311329059
   PubMed Web of Science ®Google Scholar
• XuLCochranDMTongRTPlacenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse modelsCancer Res20066683971397716618713
   PubMed Web of Science ®Google Scholar
• CaoDHouMGuanYSJiangMYangYGouHFExpression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implicationsBMC Cancer2009943220003271
   PubMed Web of Science ®Google Scholar
• YonekuraHSakuraiSLiuXPlacenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesisJ Biol Chem199927449351723517810575000
   PubMed Web of Science ®Google Scholar
• NashADBacaMWrightCScotneyPDThe biology of vascular endothelial growth factor-B (VEGF-B)Pulm Pharmacol Ther2006191616916286239
   PubMed Web of Science ®Google Scholar
• ZhangFTangZHouXVEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inh, ibits pathological angiogenesisProc Natl Acad Sci U S A2009106156152615719369214
   PubMed Web of Science ®Google Scholar
• JayasingheCSimiantonakiNKirkpatrickCJVEGF-B expression in colorectal carcinomas and its relevance for tumor progressionHistol Histopathol201328564765323417498
   PubMed Web of Science ®Google Scholar
• JussilaLAlitaloKVascular growth factors and lymphangiogenesisPhysiol Rev200282367370012087132
   PubMed Web of Science ®Google Scholar
• WangTBChenZGWeiXQWeiBDongWGSerum vascular endothelial growth factor-C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancerANZ J Surg2011811069469922295309
   PubMed Web of Science ®Google Scholar
• StackerSAAchenMGThe VEGF signaling pathway in cancer: the road aheadChin J Cancer201332629730223419196
   PubMedGoogle Scholar
• SuJLYenCJChenPSThe role of the VEGF-C/VEGFR-3 axis in cancer progressionBr J Cancer200796454154517164762
   PubMed Web of Science ®Google Scholar
• MartinsSFGarciaEALuzMAPardalFRodriguesMFilhoALClinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancerCancer Genomics Proteomics2013102556723603341
   PubMed Web of Science ®Google Scholar
• HuangHBhatAWoodnuttGLappeRTargeting the ANGPT-TIE2 pathway in malignancyNat Rev Cancer201010857558520651738
   PubMed Web of Science ®Google Scholar
• QiaoLWongBCRole of Notch signaling in colorectal cancerCarcinogenesis200930121979198619793799
   PubMed Web of Science ®Google Scholar
• JubbAMTurleyHMoellerHCExpression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancerBr J Cancer2009101101749175719844231
   PubMed Web of Science ®Google Scholar
• BeneditoRRochaSFWoesteMNotch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signallingNature2012484739211011422426001
   PubMed Web of Science ®Google Scholar
• HanrahanVCurrieMJGunninghamSPThe angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progressionJ Pathol2003200218319412754739
   PubMed Web of Science ®Google Scholar
• KangSMMaedaKOnodaNCombined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasisInt J Cancer19977455025079355971
   PubMed Web of Science ®Google Scholar
• RmaliKAPuntisMCJiangWGTumour-associated angiogenesis in human colorectal cancerColorectal Dis20079131417181841
   PubMed Web of Science ®Google Scholar
• SaifMWAnti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?Cancer Manag Res2013510311523807861
   PubMedGoogle Scholar
• SungCYSonMWAhnTSJungDJLeeMSBaekMJExpression of placenta growth factor in colorectal carcinomasJ Korean Soc Coloproctol201228631532023346511
   PubMedGoogle Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJEastern Cooperative Oncology Group Study E3200Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
   PubMed Web of Science ®Google Scholar
• ChenHXCleckJNAdverse effects of anticancer agents that target the VEGF pathwayNat Rev Clin Oncol20096846547719581909
   PubMed Web of Science ®Google Scholar
• NalluriSRChuDKeresztesRZhuXWuSRisk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysisJAMA2008300192277228519017914
   PubMed Web of Science ®Google Scholar
• HolashJDavisSPapadopoulosNVEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
   PubMed Web of Science ®Google Scholar
• WilhelmSMDumasJAdnaneLRegorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInt J Cancer2011129124525521170960
   PubMed Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroACORRECT Study GroupRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
   PubMed Web of Science ®Google Scholar
• RudgeJSHolashJHyltonDVEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockadeProc Natl Acad Sci U S A200710447183631837018000042
   PubMed Web of Science ®Google Scholar
• PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
   PubMed Web of Science ®Google Scholar
• GayaATseVA preclinical and clinical review of aflibercept for the management of cancerCancer Treat Rev201238548449322264850
   PubMed Web of Science ®Google Scholar
• LockhartACRothenbergMLDupontJPhase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumorsJ Clin Oncol201028220721419949018
   PubMed Web of Science ®Google Scholar
• YoshinoTYamazakiKYamaguchiKA phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancerInvest New Drugs201331491091723179335
   PubMed Web of Science ®Google Scholar
• Van CutsemEKhayatDVerslypeCPhase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumoursEur J Cancer2013491172422921183
   PubMed Web of Science ®Google Scholar
• KhayatDTejparSSpanoJPIntravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I studyEur J Cancer201349479079723312881
   PubMed Web of Science ®Google Scholar
• TangPACohenSJKollmannsbergerCPhase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancerClin Cancer Res201218216023603122977191
   PubMed Web of Science ®Google Scholar
• Van CutsemEPeetersMSienaSOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol200725131658166417470858
   PubMed Web of Science ®Google Scholar
• KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med2008359171757176518946061
   PubMed Web of Science ®Google Scholar
• PericayCFolprechtGSaundersMPhase 2 randomized, non-comparative, open-label study of aflibercept and modified FOLFOX6 in the first-line treatment of metastatic colorectal cancer (AFFIRM)Ann Oncol201223Supplement 4iv16
   Web of Science ®Google Scholar
• Van CutsemETaberneroJLakomyRAddition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimenJ Clin Oncol201230283499350622949147
   PubMed Web of Science ®Google Scholar
• RuffPFerryDPapamichaelDLakomyRO-0017 observed benefit of aflibercept in mCRC patients ≥65 years old: results of a pre-specified age-based analysis of the VELOUR studyAnn Oncol2013244iv18
   Google Scholar
• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med197128521118211864938153
   PubMed Web of Science ®Google Scholar
• ChuEAn update on the current and emerging targeted agents in metastatic colorectal cancerClin Colorectal Cancer201211111321752724
   PubMed Web of Science ®Google Scholar
• TroianiTMartinelliEOrdituraMDe VitaFCiardielloFMorgilloFBeyond bevacizumab: new anti-VEGF strategies in colorectal cancerExpert Opin Investig Drugs2012217949959
   PubMed Web of Science ®Google Scholar
• PetrelliFBorgonovoKCabidduMFOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trialsClin Colorectal Cancer201312314515123763824
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDíaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol200826122013201918421054
   PubMed Web of Science ®Google Scholar
• BennounaJSastreJArnoldDML18147 Study InvestigatorsContinuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialLancet Oncol2013141293723168366
   PubMed Web of Science ®Google Scholar
• GrenonNNManaging toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancerClin J Oncol Nurs201317442543323899982
   PubMed Web of Science ®Google Scholar
• MorlockRYuERayJA cost-effectiveness analysis of bevacizumab (BV) plus chemotherapy (CT) versus aflibercept (AFLI) plus CT in patients with metastatic colorectal cancer (mCRC) previously treated with BVJ Clin Oncol (Meeting Abstracts). J Clin Oncol201234 abstr 417
   Google Scholar
• KopetzSHoffPMMorrisJSPhase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceJ Clin Oncol201028345345920008624
   PubMed Web of Science ®Google Scholar
• WillettCGDudaDGdi TomasoEEfficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyJ Clin Oncol200927183020302619470921
   PubMed Web of Science ®Google Scholar
• LoupakisFCremoliniCFioravantiAPharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerBr J Cancer201110481262126921407216
   PubMed Web of Science ®Google Scholar
• FischerCJonckxBMazzoneMAnti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vesselsCell2007131346347517981115
   PubMed Web of Science ®Google Scholar
• ClarkeJMHurwitzHIUnderstanding and targeting resistance to anti-angiogenic therapiesJ Gastrointest Oncol20134325326323997938
   PubMedGoogle Scholar
• LieuCHeymachJOvermanMTranHKopetzSBeyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesisClin Cancer Res201117196130613921953501
   PubMed Web of Science ®Google Scholar
• ChenCTHungMCBeyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapyAm J Transl Res20135439340323724163
   PubMed Web of Science ®Google Scholar
• Moreno GarciaVBasuBMolifeLRKayeSBCombining antiangiogenics to overcome resistance: rationale and clinical experienceClin Cancer Res201218143750376122547772
   PubMed Web of Science ®Google Scholar
• ChauIJoulainFIqbalSA VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRIAnnal Oncol201324suppl 4iv91
   Google Scholar
• WilsonPMLaBonteMJLenzHJAssessing the in vivo efficacy of biologic antiangiogenic therapiesCancer Chemother Pharmacol201371111223053262
   PubMed Web of Science ®Google Scholar
• LambrechtsDLenzHJde HaasSCarmelietPSchererSJMarkers of response for the antiangiogenic agent bevacizumabJ Clin Oncol20133191219123023401453
   PubMed Web of Science ®Google Scholar
• AllegraCJYothersGO’ConnellMJPhase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08J Clin Oncol2011291111620940184
   PubMed Web of Science ®Google Scholar
• SnoerenNVoestEEBergmanAMA randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatmentBMC Cancer20101054520937118
   PubMed Web of Science ®Google Scholar
• KemenyNEJarnaginWRCapanuMRandomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancerJ Clin Oncol201129788488921189384
   PubMed Web of Science ®Google Scholar